STOCK TITAN

MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) will announce its Q1 2022 financial results on May 5, 2022, at 5:00 PM ET. The call will feature CEO Michael Castagna and CFO Steven Binder, discussing key financial updates and company developments. MannKind is known for its Afrezza inhaled insulin, the only ultra-rapid-acting mealtime insulin available in the U.S. and Brazil. Investors can access the live call via the company's website for comprehensive insights into performance and strategic direction during the session.

Positive
  • None.
Negative
  • None.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Thursday, May 5, 2022.

Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.

Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://mannkindcorp.com/news-events/ under Events.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

For MannKind:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com


FAQ

When will MannKind release its Q1 2022 financial results?

MannKind will release its Q1 2022 financial results on May 5, 2022.

Who will present the financial results for MannKind?

CEO Michael Castagna and CFO Steven Binder will present the financial results.

Where can I listen to MannKind's conference call?

The conference call can be accessed live on MannKind's website.

What is MannKind's main product?

MannKind's main product is Afrezza, an inhaled ultra-rapid-acting mealtime insulin.

Mannkind Corporation

NASDAQ:MNKD

MNKD Rankings

MNKD Latest News

MNKD Stock Data

1.87B
270.76M
1.83%
56.64%
15.24%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DANBURY